These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7850323)

  • 1. Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada.
    Mack D; Frick J
    Br J Urol; 1995 Feb; 75(2):185-7. PubMed ID: 7850323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer.
    Mack D; Frick J
    Urology; 1995 Jun; 45(6):958-61. PubMed ID: 7771030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder.
    Akaza H; Koiso K; Ozono S; Kuroda M; Kameyama S; Okajima E; Kotake T; Kakizoe T; Kawabe K;
    Jpn J Clin Oncol; 2003 Aug; 33(8):382-90. PubMed ID: 14523057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical BCG therapy of superficial bladder cancer: study of adverse effects.
    Galván L; Ayani I; Arrizabalaga MJ; Rodriguez-Sasiain JM
    J Clin Pharm Ther; 1994 Apr; 19(2):101-4. PubMed ID: 8071388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer.
    Saint F; Irani J; Patard JJ; Salomon L; Hoznek A; Zammattio S; Debois H; Abbou CC; Chopin DK
    Urology; 2001 May; 57(5):883-8. PubMed ID: 11337287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis.
    Wishahi MM; Ismail IM; el-Sherbini M
    Br J Urol; 1994 Jun; 73(6):649-54. PubMed ID: 8032832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer.
    Al Khalifa M; Elfving P; Månsson W; Colleen S; Hellsten S; Duchek M; Nyberg G; Callaghan P; Rademark C; Eriksson R; Olsson R; Hagberg G; Nelson CE
    Eur Urol; 2000; 37 Suppl 1():26-30. PubMed ID: 10575269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.
    Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R
    Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer.
    Bowyer L; Hall RR; Reading J; Marsh MM
    Br J Urol; 1995 Feb; 75(2):188-92. PubMed ID: 7850324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
    Pansadoro V; Emiliozzi P; de Paula F; Scarpone P; Pansadoro A; Sternberg CN
    Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
    De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
    Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
    Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
    J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.
    Steg A; Leleu C; Debré B; Boccon-Gibod L; Sicard D
    Prog Clin Biol Res; 1989; 310():325-34. PubMed ID: 2672020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical bacille Calmette-Guérin in the treatment of carcinoma in situ or high-grade superficial bladder carcinoma after radiotherapy for bladder carcinoma.
    Palou J; Sánchez-Martín FM; Rosales A; Salvador J; Algaba F; Vicente J
    BJU Int; 1999 Mar; 83(4):429-31. PubMed ID: 10210566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?
    Pagano F; Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A
    J Urol; 1991 Jul; 146(1):32-5. PubMed ID: 2056600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.